Side-by-Side Comparison
TB-500 vs GHK-Cu: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how TB-500 and GHK-Cu differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
TB-500
L3Also: Thymosin Beta-4, TB4, Tβ4
A naturally occurring peptide central to cell migration and tissue repair. Phase 2 human wound healing trials showed accelerated healing; also studied for cardiac and corneal repair.
GHK-Cu
L3Also: Copper Peptide, Glycyl-L-histidyl-L-lysine:copper(II), Copper Tripeptide-1
A naturally occurring copper-binding tripeptide with research supporting skin remodeling, wound healing, and anti-aging properties.
Side-by-side comparison
| Attribute | TB-500 | GHK-Cu |
|---|---|---|
| Primary mechanism | Actin Sequestration & Cell Migration | Copper-Dependent Gene Modulation |
| FDA status | Banned from Compounding (Category 2) | Research Only |
| Evidence level | Emerging Clinical Evidence | Emerging Clinical Evidence |
| Human trials | Yes (3+ indexed) | Yes (5+ indexed) |
| Studies indexed | 119 total (4 human, 85 animal) | 96 total (8 human, 42 animal) |
| Primary uses researched | Wound healing, Tissue repair, Anti-inflammatory, Hair growth | Skin rejuvenation, Wound healing, Hair growth, Anti-aging |
| Administration routes | subcutaneous | subcutaneous, topical |
| Molecular weight | 4963.50 Da | 403.93 Da |
| Amino acids | 43 | 3 |
| Category | healing recovery | skin hair |
| WADA status | Prohibited | Permitted |
Key differences
Mechanism. TB-500 acts primarily through actin sequestration & cell migration, while GHK-Cu acts primarily through copper-dependent gene modulation. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. TB-500 is classified as banned from compounding (category 2); GHK-Cu is classified as research only. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Both compounds currently sit at L3 (Emerging Clinical Evidence) on PeptideMark's methodology.
Research focus. Published research on TB-500 has concentrated on wound healing, tissue repair, anti-inflammatory. Research on GHK-Cu has concentrated on skin rejuvenation, wound healing, hair growth. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | TB-500 | GHK-Cu |
|---|---|---|
| Documented effects | 6 total | 4 total |
| Serious events | 0 | 0 |
| Common events | 1 | 0 |
| Black box warning | No | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | — |
Strengths & limitations
TB-500
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Prohibited in competitive sport under WADA
GHK-Cu
Strengths
- Multiple human clinical trials (5+ indexed)
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
Representative studies
TB-500
Thymosin beta4 accelerates wound healing
Malinda KM, Sidhu GS, Mani H, et al. · Journal of Investigative Dermatology (1999)
Thymosin beta-4 accelerated wound healing by 42-61% and increased wound contraction by 11% through enhanced keratinocyte migration and angiogenesis.
PubMed 10469335Thymosin beta 4 promotes dermal wound healing and angiogenesis in vivo
Philp D, Goldstein AL, Kleinman HK. · Annals of the New York Academy of Sciences (2004)
Tβ4 accelerated wound closure across all animal models tested, with enhanced angiogenesis and hair follicle stem cell activation.
PubMed 15539408GHK-Cu
GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration
Pickart L, Vasquez-Soltero JM, Margolina A. · BioMed Research International (2015)
GHK-Cu modulates 32% of human genes, upregulating repair/anti-inflammatory pathways and downregulating tissue destruction pathways — a broad anti-aging gene expression signature.
PubMed 25861628The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Pickart L, Vasquez-Soltero JM, Margolina A. · Oxidative Medicine and Cellular Longevity (2012)
GHK-Cu acts as a potent antioxidant and anti-degenerative agent through copper delivery, ECM remodeling, and upregulation of endogenous antioxidant defenses.
PubMed 22900137Frequently asked
What is the main difference between TB-500 and GHK-Cu?
TB-500 is a naturally occurring peptide central to cell migration and tissue repair. phase 2 human wound healing trials showed accelerated healing; also studied for cardiac and corneal repair. Its primary mechanism is actin sequestration & cell migration. GHK-Cu is a naturally occurring copper-binding tripeptide with research supporting skin remodeling, wound healing, and anti-aging properties. Its primary mechanism is copper-dependent gene modulation. The two differ in regulatory status (Banned from Compounding (Category 2) vs Research Only), strength of evidence (L3 vs L3), and the primary conditions for which each is researched.
Is TB-500 or GHK-Cu FDA approved?
TB-500: Thymosin beta-4 placed on FDA Category 2 list in late 2023. Not approved for human use. Was previously available through compounding pharmacies. GHK-Cu: Not FDA-approved as a drug. Available in cosmetic products. Not on Category 2 list. Research compound for injectable use.
How does the evidence base compare?
TB-500 has 119 indexed studies (4 human, 85 animal) and is rated Emerging Clinical Evidence. GHK-Cu has 96 indexed studies (8 human, 42 animal) and is rated Emerging Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can TB-500 and GHK-Cu be compared directly?
TB-500 and GHK-Cu come from different therapeutic categories (healing recovery vs skin hair), so direct clinical comparison is limited. Readers often compare them because of overlapping research interest, shared patient populations, or adjacent mechanisms — not because head-to-head trial data exists.
Are TB-500 and GHK-Cu commonly stacked together?
There is no widely documented stacking protocol combining TB-500 and GHK-Cu in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, TB-500 or GHK-Cu?
TB-500 has 6 documented side effects (0 serious). GHK-Cu has 4 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are TB-500 and GHK-Cu administered?
TB-500 is typically administered via subcutaneous. GHK-Cu is typically administered via subcutaneous or topical. Route differences affect onset, peak levels, and patient convenience.
Which is better, TB-500 or GHK-Cu?
"Better" depends on the therapeutic goal, regulatory context, and individual response. TB-500 is most researched for wound healing and tissue repair; GHK-Cu is most researched for skin rejuvenation and wound healing. FDA status also matters: Banned from Compounding (Category 2) for TB-500 vs Research Only for GHK-Cu. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
TB-500 →
Full profile
GHK-Cu →